| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gas Chromatography-Mass Spectrometry | 3 | 2024 | 83 | 2.510 |
Why?
|
| Drug Contamination | 4 | 2025 | 11 | 2.150 |
Why?
|
| Neuroblastoma | 5 | 2024 | 136 | 1.990 |
Why?
|
| RNA, Untranslated | 9 | 2026 | 50 | 1.890 |
Why?
|
| Methyltransferases | 3 | 2024 | 68 | 1.820 |
Why?
|
| Limit of Detection | 4 | 2025 | 94 | 1.290 |
Why?
|
| Antineoplastic Agents | 3 | 2026 | 1019 | 1.150 |
Why?
|
| Solvents | 2 | 2024 | 113 | 1.050 |
Why?
|
| Drosophila melanogaster | 3 | 2018 | 193 | 1.050 |
Why?
|
| MicroRNAs | 3 | 2026 | 518 | 1.040 |
Why?
|
| Gene Expression Profiling | 5 | 2026 | 704 | 1.020 |
Why?
|
| Contrast Media | 2 | 2025 | 103 | 1.020 |
Why?
|
| Indazoles | 1 | 2026 | 12 | 0.960 |
Why?
|
| Apoptosis | 7 | 2023 | 1568 | 0.950 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2021 | 17 | 0.950 |
Why?
|
| RNA | 4 | 2023 | 266 | 0.930 |
Why?
|
| Polychlorinated Biphenyls | 2 | 2025 | 46 | 0.930 |
Why?
|
| Gadolinium | 1 | 2025 | 30 | 0.920 |
Why?
|
| Chromatin | 6 | 2018 | 186 | 0.910 |
Why?
|
| Sulfonamides | 1 | 2026 | 91 | 0.910 |
Why?
|
| Doxorubicin | 1 | 2025 | 97 | 0.880 |
Why?
|
| Neural Crest | 1 | 2024 | 27 | 0.870 |
Why?
|
| Dimethylamines | 1 | 2024 | 1 | 0.870 |
Why?
|
| Dimethylformamide | 1 | 2024 | 8 | 0.870 |
Why?
|
| Cell Line, Tumor | 14 | 2026 | 2676 | 0.860 |
Why?
|
| Drug Design | 1 | 2026 | 186 | 0.850 |
Why?
|
| o-Phthalaldehyde | 1 | 2024 | 4 | 0.850 |
Why?
|
| Ethylenediamines | 1 | 2024 | 8 | 0.840 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2021 | 40 | 0.840 |
Why?
|
| Humans | 50 | 2026 | 43102 | 0.830 |
Why?
|
| Environmental Pollutants | 2 | 2025 | 201 | 0.800 |
Why?
|
| Metabolic Diseases | 1 | 2023 | 40 | 0.790 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 62 | 0.780 |
Why?
|
| Fatty Liver | 1 | 2023 | 77 | 0.770 |
Why?
|
| Furin | 1 | 2022 | 6 | 0.740 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2022 | 21 | 0.730 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 127 | 0.720 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 587 | 0.720 |
Why?
|
| Cell Differentiation | 1 | 2024 | 638 | 0.690 |
Why?
|
| Guanine | 1 | 2021 | 44 | 0.690 |
Why?
|
| DNA Damage | 3 | 2020 | 356 | 0.680 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 224 | 0.670 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 306 | 0.650 |
Why?
|
| Ovarian Neoplasms | 2 | 2025 | 415 | 0.640 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 12 | 0.620 |
Why?
|
| Gamma Rays | 1 | 2019 | 27 | 0.620 |
Why?
|
| Genomic Imprinting | 5 | 2013 | 35 | 0.620 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2024 | 968 | 0.610 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 61 | 0.600 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2018 | 74 | 0.590 |
Why?
|
| Histones | 6 | 2021 | 197 | 0.590 |
Why?
|
| Drosophila Proteins | 2 | 2018 | 188 | 0.580 |
Why?
|
| Cell Proliferation | 5 | 2026 | 1455 | 0.570 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 760 | 0.560 |
Why?
|
| SOX9 Transcription Factor | 1 | 2018 | 10 | 0.560 |
Why?
|
| Fibroblasts | 1 | 2019 | 281 | 0.550 |
Why?
|
| Immunoprecipitation | 1 | 2018 | 127 | 0.540 |
Why?
|
| Benzoxazoles | 1 | 2017 | 10 | 0.530 |
Why?
|
| Epigenesis, Genetic | 5 | 2021 | 291 | 0.530 |
Why?
|
| Reproducibility of Results | 6 | 2025 | 1081 | 0.520 |
Why?
|
| Triazoles | 1 | 2017 | 102 | 0.490 |
Why?
|
| RNA, Viral | 3 | 2023 | 321 | 0.490 |
Why?
|
| Gene Expression Regulation | 4 | 2018 | 1070 | 0.490 |
Why?
|
| Animals | 23 | 2025 | 16992 | 0.470 |
Why?
|
| Transcription, Genetic | 5 | 2018 | 592 | 0.460 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2026 | 157 | 0.450 |
Why?
|
| Linear Models | 3 | 2025 | 317 | 0.440 |
Why?
|
| Fas Ligand Protein | 2 | 2025 | 17 | 0.440 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2025 | 241 | 0.430 |
Why?
|
| T-Lymphocytes | 3 | 2025 | 386 | 0.410 |
Why?
|
| Immunotherapy | 3 | 2025 | 144 | 0.390 |
Why?
|
| Benzimidazoles | 2 | 2025 | 43 | 0.380 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2022 | 20 | 0.380 |
Why?
|
| Mice | 15 | 2025 | 6644 | 0.360 |
Why?
|
| Pilot Projects | 2 | 2026 | 760 | 0.360 |
Why?
|
| Hepacivirus | 2 | 2008 | 74 | 0.350 |
Why?
|
| Cephalometry | 1 | 2011 | 5 | 0.350 |
Why?
|
| Gene Silencing | 6 | 2013 | 154 | 0.350 |
Why?
|
| Skull | 1 | 2011 | 28 | 0.340 |
Why?
|
| Cell Line | 6 | 2019 | 1410 | 0.330 |
Why?
|
| Face | 1 | 2011 | 40 | 0.330 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2021 | 39 | 0.330 |
Why?
|
| Evolution, Molecular | 3 | 2025 | 307 | 0.320 |
Why?
|
| Neoplasms | 4 | 2025 | 1377 | 0.320 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 174 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 306 | 0.300 |
Why?
|
| Chromatin Assembly and Disassembly | 3 | 2018 | 45 | 0.300 |
Why?
|
| Glycolysis | 2 | 2019 | 71 | 0.290 |
Why?
|
| Ribonucleoproteins | 1 | 2008 | 31 | 0.290 |
Why?
|
| Protein Biosynthesis | 2 | 2008 | 132 | 0.290 |
Why?
|
| Autoantigens | 1 | 2008 | 87 | 0.280 |
Why?
|
| Karyopherins | 2 | 2025 | 7 | 0.270 |
Why?
|
| Algorithms | 1 | 2011 | 509 | 0.270 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 307 | 0.270 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2025 | 66 | 0.270 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2025 | 213 | 0.260 |
Why?
|
| Antiviral Agents | 2 | 2025 | 195 | 0.260 |
Why?
|
| Slovakia | 2 | 2025 | 9 | 0.250 |
Why?
|
| Epitopes | 2 | 2023 | 157 | 0.240 |
Why?
|
| Nasal Mucosa | 1 | 2025 | 35 | 0.240 |
Why?
|
| Elasticity | 1 | 2025 | 53 | 0.240 |
Why?
|
| Female | 13 | 2026 | 24698 | 0.230 |
Why?
|
| RNA, Antisense | 3 | 2011 | 18 | 0.230 |
Why?
|
| Fibrinolysin | 1 | 2025 | 9 | 0.230 |
Why?
|
| Receptors, Immunologic | 1 | 2025 | 73 | 0.230 |
Why?
|
| Tranexamic Acid | 1 | 2025 | 3 | 0.230 |
Why?
|
| Antifibrinolytic Agents | 1 | 2025 | 4 | 0.230 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2025 | 51 | 0.230 |
Why?
|
| Photochemotherapy | 1 | 2025 | 43 | 0.230 |
Why?
|
| Maternal Exposure | 1 | 2025 | 57 | 0.220 |
Why?
|
| Acetates | 1 | 2025 | 32 | 0.220 |
Why?
|
| Stress, Mechanical | 1 | 2025 | 164 | 0.220 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2025 | 61 | 0.220 |
Why?
|
| Piperidines | 1 | 2025 | 83 | 0.220 |
Why?
|
| Quinolines | 1 | 2025 | 78 | 0.220 |
Why?
|
| Adenosine | 1 | 2024 | 62 | 0.220 |
Why?
|
| Adaptation, Physiological | 1 | 2025 | 143 | 0.220 |
Why?
|
| Benzoates | 1 | 2024 | 17 | 0.220 |
Why?
|
| Virus Replication | 2 | 2025 | 318 | 0.210 |
Why?
|
| Structure-Activity Relationship | 1 | 2026 | 506 | 0.210 |
Why?
|
| Adenine | 1 | 2024 | 46 | 0.210 |
Why?
|
| Amino Acid Sequence | 2 | 2022 | 1180 | 0.210 |
Why?
|
| Polymers | 1 | 2025 | 155 | 0.210 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2025 | 188 | 0.210 |
Why?
|
| Molecular Structure | 1 | 2026 | 570 | 0.210 |
Why?
|
| Male | 10 | 2026 | 23409 | 0.210 |
Why?
|
| Indoles | 1 | 2025 | 187 | 0.210 |
Why?
|
| Benzamides | 1 | 2024 | 81 | 0.200 |
Why?
|
| Telomere | 1 | 2024 | 59 | 0.200 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2025 | 192 | 0.200 |
Why?
|
| Pharmaceutical Preparations | 1 | 2024 | 94 | 0.200 |
Why?
|
| Antibodies | 1 | 2023 | 144 | 0.200 |
Why?
|
| Cricetulus | 2 | 2020 | 82 | 0.190 |
Why?
|
| Methylation | 1 | 2023 | 119 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2026 | 1124 | 0.190 |
Why?
|
| District of Columbia | 1 | 2022 | 80 | 0.190 |
Why?
|
| Case-Control Studies | 1 | 2026 | 1285 | 0.190 |
Why?
|
| Gene Expression | 1 | 2025 | 701 | 0.190 |
Why?
|
| Dyslipidemias | 1 | 2022 | 48 | 0.180 |
Why?
|
| Cell Survival | 1 | 2025 | 945 | 0.180 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 10 | 0.180 |
Why?
|
| Virus Internalization | 1 | 2022 | 36 | 0.180 |
Why?
|
| Apolipoproteins E | 1 | 2022 | 138 | 0.180 |
Why?
|
| Green Chemistry Technology | 3 | 2025 | 6 | 0.170 |
Why?
|
| Immune Evasion | 1 | 2021 | 17 | 0.170 |
Why?
|
| Insulin-Secreting Cells | 1 | 2021 | 28 | 0.170 |
Why?
|
| rho-Associated Kinases | 1 | 2021 | 36 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2020 | 5 | 0.160 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2018 | 31 | 0.160 |
Why?
|
| Genomics | 1 | 2022 | 293 | 0.160 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 115 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2022 | 209 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 1 | 2022 | 386 | 0.160 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2013 | 300 | 0.160 |
Why?
|
| Mitochondria | 3 | 2020 | 523 | 0.160 |
Why?
|
| Chromatids | 1 | 2019 | 2 | 0.160 |
Why?
|
| Carbocyanines | 1 | 2019 | 14 | 0.160 |
Why?
|
| Karyotyping | 1 | 2019 | 45 | 0.160 |
Why?
|
| Aneuploidy | 1 | 2019 | 24 | 0.160 |
Why?
|
| Adult | 4 | 2026 | 13872 | 0.150 |
Why?
|
| Environmental Exposure | 1 | 2022 | 256 | 0.150 |
Why?
|
| Nanoparticles | 1 | 2025 | 460 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2020 | 91 | 0.150 |
Why?
|
| Middle Aged | 3 | 2026 | 12222 | 0.150 |
Why?
|
| Chromosomes | 1 | 2019 | 43 | 0.150 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2019 | 17 | 0.150 |
Why?
|
| Body Weight | 1 | 2021 | 429 | 0.150 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2019 | 90 | 0.150 |
Why?
|
| Aerobiosis | 1 | 2019 | 15 | 0.150 |
Why?
|
| Whole Body Imaging | 1 | 2019 | 25 | 0.150 |
Why?
|
| Comet Assay | 1 | 2019 | 77 | 0.150 |
Why?
|
| Gallbladder Neoplasms | 1 | 2018 | 3 | 0.150 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2025 | 465 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 220 | 0.140 |
Why?
|
| Mitosis | 1 | 2019 | 114 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 220 | 0.140 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 78 | 0.140 |
Why?
|
| Ubiquitination | 1 | 2018 | 62 | 0.140 |
Why?
|
| Phosphorylation | 2 | 2019 | 986 | 0.140 |
Why?
|
| DNA Methylation | 2 | 2012 | 403 | 0.140 |
Why?
|
| DNA Repair | 1 | 2019 | 198 | 0.140 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2018 | 32 | 0.140 |
Why?
|
| Workflow | 1 | 2018 | 26 | 0.140 |
Why?
|
| Cell Cycle | 1 | 2019 | 346 | 0.140 |
Why?
|
| S Phase | 1 | 2018 | 36 | 0.140 |
Why?
|
| Reactive Oxygen Species | 2 | 2019 | 532 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2022 | 1546 | 0.130 |
Why?
|
| Organogenesis | 1 | 2017 | 16 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 290 | 0.130 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2018 | 57 | 0.130 |
Why?
|
| Eye | 1 | 2018 | 77 | 0.130 |
Why?
|
| Caspases | 1 | 2017 | 148 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 223 | 0.120 |
Why?
|
| Lung | 1 | 2019 | 492 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 3 | 2018 | 526 | 0.120 |
Why?
|
| KCNQ1 Potassium Channel | 2 | 2012 | 2 | 0.120 |
Why?
|
| Antioxidants | 1 | 2019 | 443 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 347 | 0.110 |
Why?
|
| Neuropeptides | 1 | 2015 | 64 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2025 | 2157 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 46 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 561 | 0.110 |
Why?
|
| Protein Conformation | 2 | 2021 | 416 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 216 | 0.100 |
Why?
|
| Child | 1 | 2022 | 3443 | 0.100 |
Why?
|
| Models, Biological | 1 | 2017 | 712 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 257 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 495 | 0.100 |
Why?
|
| Protein Binding | 3 | 2025 | 1082 | 0.100 |
Why?
|
| Conserved Sequence | 2 | 2010 | 122 | 0.100 |
Why?
|
| DNA | 1 | 2015 | 592 | 0.090 |
Why?
|
| Cell Nucleolus | 2 | 2008 | 11 | 0.090 |
Why?
|
| United States | 1 | 2022 | 5205 | 0.090 |
Why?
|
| Radiography | 1 | 2011 | 71 | 0.090 |
Why?
|
| Head | 1 | 2011 | 28 | 0.090 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 51 | 0.080 |
Why?
|
| Postpartum Hemorrhage | 1 | 2010 | 18 | 0.080 |
Why?
|
| Radiation Dosage | 2 | 2021 | 37 | 0.080 |
Why?
|
| DNA, Intergenic | 1 | 2010 | 11 | 0.080 |
Why?
|
| Mice, SCID | 2 | 2021 | 158 | 0.080 |
Why?
|
| Young Adult | 1 | 2021 | 5080 | 0.080 |
Why?
|
| Introns | 1 | 2010 | 79 | 0.080 |
Why?
|
| Brain | 1 | 2018 | 1472 | 0.080 |
Why?
|
| High-Throughput Screening Assays | 1 | 2010 | 74 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2011 | 341 | 0.080 |
Why?
|
| Mammals | 1 | 2010 | 112 | 0.080 |
Why?
|
| Cell Movement | 2 | 2025 | 655 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 1542 | 0.070 |
Why?
|
| Ribosomes | 1 | 2008 | 35 | 0.070 |
Why?
|
| DNA, Catalytic | 1 | 2008 | 2 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 1869 | 0.070 |
Why?
|
| Binding Sites | 2 | 2021 | 671 | 0.070 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 82 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 515 | 0.070 |
Why?
|
| Pregnancy | 3 | 2025 | 1772 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 301 | 0.070 |
Why?
|
| India | 2 | 2021 | 108 | 0.060 |
Why?
|
| Mutation | 3 | 2021 | 1177 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2021 | 1621 | 0.060 |
Why?
|
| Interferons | 1 | 2025 | 40 | 0.060 |
Why?
|
| Cilia | 1 | 2025 | 31 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2025 | 23 | 0.060 |
Why?
|
| Myosin Type II | 1 | 2025 | 17 | 0.060 |
Why?
|
| Fetal Blood | 1 | 2025 | 48 | 0.060 |
Why?
|
| Tablets | 1 | 2025 | 14 | 0.060 |
Why?
|
| Macaca mulatta | 1 | 2025 | 139 | 0.060 |
Why?
|
| Cyclopropanes | 1 | 2025 | 46 | 0.060 |
Why?
|
| Hydrogen Bonding | 1 | 2025 | 144 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2025 | 97 | 0.060 |
Why?
|
| Drug Stability | 1 | 2025 | 129 | 0.050 |
Why?
|
| Sulfides | 1 | 2025 | 78 | 0.050 |
Why?
|
| Temperature | 1 | 2025 | 313 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2008 | 561 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2025 | 182 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1271 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2024 | 60 | 0.050 |
Why?
|
| Pakistan | 1 | 2022 | 20 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2025 | 972 | 0.050 |
Why?
|
| PPAR alpha | 1 | 2022 | 42 | 0.050 |
Why?
|
| Triglycerides | 1 | 2022 | 147 | 0.050 |
Why?
|
| CpG Islands | 2 | 2012 | 109 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2021 | 76 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 84 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2021 | 16 | 0.040 |
Why?
|
| Cell Fractionation | 1 | 2020 | 29 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 232 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2025 | 735 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 256 | 0.040 |
Why?
|
| Staphylococcal Protein A | 1 | 2020 | 1 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2020 | 39 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2020 | 154 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 389 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 189 | 0.040 |
Why?
|
| CHO Cells | 1 | 2020 | 123 | 0.040 |
Why?
|
| Kinetics | 1 | 2021 | 695 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 240 | 0.040 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2019 | 1 | 0.040 |
Why?
|
| Hexokinase | 1 | 2019 | 10 | 0.040 |
Why?
|
| Micronucleus Tests | 1 | 2019 | 16 | 0.040 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2019 | 5 | 0.040 |
Why?
|
| Pyruvate Dehydrogenase (Lipoamide)-Phosphatase | 1 | 2019 | 2 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2019 | 64 | 0.040 |
Why?
|
| Pyruvic Acid | 1 | 2019 | 22 | 0.040 |
Why?
|
| RNA Polymerase II | 2 | 2009 | 31 | 0.040 |
Why?
|
| Heme | 1 | 2019 | 72 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2020 | 383 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2019 | 70 | 0.040 |
Why?
|
| Potassium Channels, Voltage-Gated | 2 | 2008 | 13 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 81 | 0.040 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2018 | 1 | 0.040 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2018 | 2 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 536 | 0.040 |
Why?
|
| RNA Interference | 1 | 2019 | 247 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2019 | 112 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 237 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 92 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 508 | 0.030 |
Why?
|
| Hela Cells | 1 | 2018 | 376 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 200 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 457 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2018 | 408 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 1857 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 436 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 694 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 456 | 0.030 |
Why?
|
| Base Sequence | 2 | 2008 | 983 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1035 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 861 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 129 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2014 | 63 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 287 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2012 | 48 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2012 | 19 | 0.020 |
Why?
|
| Homozygote | 1 | 2012 | 77 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 667 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2014 | 273 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2011 | 30 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 93 | 0.020 |
Why?
|
| Lysine | 1 | 2011 | 119 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2011 | 83 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 157 | 0.020 |
Why?
|
| Placenta | 1 | 2011 | 117 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2011 | 192 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 185 | 0.020 |
Why?
|
| Testis | 1 | 2011 | 207 | 0.020 |
Why?
|
| Spermatogenesis | 1 | 2011 | 161 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 236 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 863 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 665 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 423 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 352 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2008 | 12 | 0.020 |
Why?
|
| RNA Stability | 1 | 2008 | 28 | 0.020 |
Why?
|
| Enterovirus B, Human | 1 | 2008 | 2 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2008 | 150 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2008 | 148 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2008 | 154 | 0.020 |
Why?
|
| Plasmids | 1 | 2008 | 244 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2008 | 190 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2010 | 1600 | 0.020 |
Why?
|
| Risk Factors | 1 | 2010 | 3994 | 0.010 |
Why?
|